AzTrials
AzTrials

PsoriasisPhase 4NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

A Phase 4 study testing In situ cutaneous microdevice, Triamcinolone and 5-Fluorouracil in people with Psoriasis and Atopic Dermatitis, run by University of California, San Francisco at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriasis, Atopic Dermatitis
What is being tested?
In situ cutaneous microdevice, Triamcinolone and 5-Fluorouracil
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
1 Aug 2026to 1 Jun 2030
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • > 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days)

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Raymond Cho, MD, PhD contact

415-353-7800

raymond.cho@ucsf.edu

Jeffrey Cheng, MD, PhD contact

415-575-0524

jeffrey.cheng@ucsf.edu

United States1 site

  • University of California, San Francisco

    San Francisco, California, 94158

Other trials in United States

About this study

Official title: Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Being tested
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof
Medical subject headings
Psoriasis, Dermatitis, Atopic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • In situ cutaneous microdeviceDevice

    The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.

  • TriamcinoloneDrug

    Triamcinolone

  • 5-FluorouracilDrug

    5-fluorouracil

  • CalcipotrieneDrug

    Calcipotriene

  • TapinarofDrug

    Tapinarof

  • CrisaboroleDrug

    Crisaborole

  • TacrolimusDrug

    Tacrolimus

  • AdalimumabDrug

    Adalimumab

  • EtanerceptDrug

    Etanercept

  • CertolizumabDrug

    Certolizumab

  • InfliximabDrug

    Infliximab

  • SecukinumabDrug

    Secukinumab

  • IxekizumabDrug

    Ixekizumab

  • ApremilastDrug

    Apremilast

  • RisankizumabDrug

    Risankizumab

  • UstekinumabDrug

    Ustekinumab

  • HydroxychloroquineDrug

    Hydroxychloroquine

  • MethotrexateDrug

    Methotrexate

  • MycophenolateDrug

    Mycophenolate

  • AzathioprineDrug

    Azathioprine

  • ChloroquineDrug

    Chloroquine

  • CyclosporineDrug

    Cyclosporine

  • TofacitinibDrug

    Tofacitinib

  • DeucravacitinibDrug

    Deucravacitinib

  • DupilumabDrug

    Dupilumab

  • TralokinumabDrug

    Tralokinumab

  • GuselkumabDrug

    Guselkumab

  • TildrakizumabDrug

    Tildrakizumab

  • BaractinibDrug

    Baractinib

  • AbrocitinibDrug

    Abrocitinib

  • UpadacitinibDrug

    Upadacitinib

  • LebrikizumabDrug

    Lebrikizumab

  • NemolizumabDrug

    Nemolizumab

  • RuxolitinibDrug

    Ruxolitinib

  • BimekizumabDrug

    Bimekizumab

  • RoflumilastDrug

    Roflumilast

Study groups in NCT07352566
Study groupRoleWhat they receive
In situ cutaneous microdeviceExperimentalThe small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Receives: Device: In situ cutaneous microdevice; Drug: Triamcinolone; Drug: 5-Fluorouracil; Drug: Calcipotriene; Drug: Tapinarof; Drug: Crisaborole; Drug: Tacrolimus; Drug: Adalimumab; Drug: Etanercept; Drug: Certolizumab; Drug: Infliximab; Drug: Secukinumab; Drug: Ixekizumab; Drug: Apremilast; Drug: Risankizumab; Drug: Ustekinumab; Drug: Hydroxychloroquine; Drug: Methotrexate; Drug: Mycophenolate; Drug: Azathioprine; Drug: Chloroquine; Drug: Cyclosporine; Drug: Tofacitinib; Drug: Deucravacitinib; Drug: Dupilumab; Drug: Tralokinumab; Drug: Guselkumab; Drug: Tildrakizumab; Drug: Baractinib; Drug: Abrocitinib; Drug: Upadacitinib; Drug: Lebrikizumab; Drug: Nemolizumab; Drug: Ruxolitinib; Drug: Bimekizumab; Drug: Roflumilast

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with adverse events

    The safety of microdevice placement and removal will be based on assessment of adverse events.

    Measured: 1 year

  2. Proportion of retrieved devices with assessable tissue

    The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.

    Measured: 1 year

Secondary outcomes (1)

  1. Change in local skin inflammation (molecular assays)

    Feasibility of utilizing quantitative histopathologic assessment and/or transcriptional profiling to determine whether there is local change in lesional rash-affected skin with clinically relevant skin inflammation treating agents.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2026
  2. Study start1 Aug 2026 (estimated)
  3. Primary completion1 Jun 2030 (estimated)
  4. Study completion1 Jun 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07352566
Sponsor's protocol ID
25-43621
Status last verified
Jun 2026
First submitted
17 Nov 2025
Last updated
3 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tsai LL, Phillips WW, Hung YP, Dominas C, Deans K, Ahn S, Ferland B, Weiss K, Lanuti M, Auchincloss H, Schumacher L, Jonas O, Colson YL. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer. Ann Surg. 2023 May 1;277(5):e1143-e1149. doi: 10.1097/SLA.0000000000005385. Epub 2023 Apr 6.

    PubMed 35129472

  • Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin PJ, Ahn SW, Mills GB, Coussens LM, Jonas O, Gray JW. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nat Biotechnol. 2022 Dec;40(12):1823-1833. doi: 10.1038/s41587-022-01379-y. Epub 2022 Jul 4.

    PubMed 35788566

  • Peruzzi P, Dominas C, Fell G, Bernstock JD, Blitz S, Mazzetti D, Zdioruk M, Dawood HY, Triggs DV, Ahn SW, Bhagavatula SK, Davidson SM, Tatarova Z, Pannell M, Truman K, Ball A, Gold MP, Pister V, Fraenkel E, Chiocca EA, Ligon KL, Wen PY, Jonas O. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Sci Transl Med. 2023 Sep 6;15(712):eadi0069. doi: 10.1126/scitranslmed.adi0069. Epub 2023 Sep 6.

    PubMed 37672566

  • Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI, Cima MJ, Langer R. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med. 2015 Apr 22;7(284):284ra57. doi: 10.1126/scitranslmed.3010564.

    PubMed 25904741

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing In situ cutaneous microdevice, Triamcinolone and 5-Fluorouracil in people with Psoriasis and Atopic Dermatitis, run by University of California, San Francisco at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Raymond Cho, MD, PhD (415-353-7800, raymond.cho@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with adverse events (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07352566, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in